Hoechst Aktiengesellschaft

Wilhelm Bartmann

Gerhard Beck

Ulrich Lerch

Gunther Wess

Milos Babej

Hans-Hermann Lau

Ernold Granzer

Elmar Konz

Hermann Teufel

Bernward Scholkens

Rudolf Kunstmann

Josef Musil

Dieter-Bernd Reuschling

Joachim Kaiser

Klaus Kuhlein

Rudolf Lattrell

Hansjorg Kruse

Kurt Kesseler

Harry M Geyer

Martin Bickel

Hansjorg Urbach

Jochen Knolle

Hermann J Gerhards

Karl Seeger

Richard H Rupp

Wolfgang Ruger

Hiristo Anagnostopulos

Heiner Jendralla

Andreas Bergmann

Bernward Schokens

6-Fluoro-3,5-dihydroxy carboxylic acid derivatives of the formula I and the corresponding lactones of the formula II ##STR1## in which R.sup.1 and R.sup.2 have the specified meanings, a process for the preparation of these compounds, the use thereof as medicinal agents and pharmaceutical products are described. In addition, new intermediates for the preparation of the compounds of the formula I or formula II are described.

6-fluoro-3,5-dihydroxy carboxylic acids and derivatives thereof

6-Phenoxymethyl-4-hydroxytetrahydropyran-2-ones and 6-thiophenoxymethyl-4-hydroxytetrahydropyran-2-ones and the corresponding dihydroxycarboxylic acid derivatives, salts and esters, processes for the preparation of these compounds, their use as pharmaceuticals, pharmaceutical preparations and novel phenols and thiophenols Compounds of the general formula I ##STR1## and the corresponding open-chain dihydroxycarboxylic acids of the formula II ##STR2## in which X, Y and Z have the meanings given, and pharmacologically tolerated salts thereof with bases and pharmacologically tolerated esters thereof, processes for the preparation of these compounds, their use as pharmaceuticals and pharmaceutical preparations are described. Novel phenols and thiophenols of the formula III ##STR3## in which X, Y and Z have the meanings given, are also described.

6-phenoxymethyl-4-hydroxytetrahydropyran-2-ones and

7-Substituted 3,5-dihydroxyhept-6-ynoic acids and the derivatives thereof of the formula I ##STR1## as well as the corresponding lactones of the formula II ##STR2## in which R and R.degree. have the specified meanings, a process for the preparation of these compounds, the use thereof as pharmaceuticals and pharmaceutical products are described. In addition, new intermediates for the preparation of the compounds of the formula I or formula II are described.

7-substituted derivatives of 3,5-dihydroxyhept-6-ynoic acids and

3-Demethylmevalonic acid derivatives of the formula I (.delta.-lactone) and II (corresponding dihydroxy carboxylic acid derivative) ##STR1## in which A--B, Z, R.sup.1, R.sup.2, R.sup.3 and R.sup.4 have the indicated meanings, a process for the preparation of these compounds, their use as medicaments, and pharmaceutical products, are described. In addition, new intermediates for the preparation of the compounds of the formula I and formula II are described.

3-demethylmevalonic acid derivatives, and pharmaceutical products based

A compound I ##STR1## in which R.sup.1 is cycloalkyl, alkenyl, cycloalkenyl, phenyl, ##STR2## where

Diarylalkyl-substituted alkylamines and medicaments containing them

3-Demethyl-4-fluoromevalonic acid derivatives, a process for the preparation thereof, pharmaceutical products based on these compounds, the use thereof, and intermediates 3-Demethyl-4-fluoromevalonic acid derivatives of the formula I, and the corresponding dihydroxy carboxylic acid derivatives of the formula II ##STR1## in which R, X and Y have the stated meanings, processes for the preparation of these compounds, the use thereof as medicaments, and pharmaceutical products are described. In addition, new intermediates for the preparation of the compounds of the formula I and formula II are described.

3-demethyl-4-fluoromevalonic acid derivatives, a process for the

Leukotriene antagonists, a process for the preparation thereof, and the use thereof for the treatment of diseases ##STR1## in which R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5 and X have the indicated meanings, a process for the preparation of these compounds, the use thereof as pharmaceuticals, and pharmaceutical products based on these compounds, are described.

Leukotriene antagonists, a process for the preparation thereof, and the

Compounds of the formula I ##STR1## in which R.sup.1, R.sup.2 and Y have the indicated meanings, their physiologically tolerated acid addition salts, and a process for the preparation of these compounds are described. The compounds inhibit thromboxane synthetase and can thus be used as medicaments.

Naphthyl imidazolyl compounds and pharmaceutical compositions

The present invention relates to new pyridines substituted in the 3-position, of the formula ##STR1## and to a process for their preparation. The compounds bring about specific inhibition of thromboxane synthetase and can thus be used as medicaments.

3-pyridyl compounds and use as thromboxane synthetase inhibitors

Compounds of the formula I ##STR1## in which R.sup.1, R.sup.2, R.sup.3 and Y have the indicated meanings, their physiologically tolerated acid addition salts, and a process for the preparation of these compounds, are described. The compounds inhibit thromboxane synthetase and can thus be used as medicaments.

3-pyridylmethylnaphthyl derivatives and composition containing them

The present invention relates to new ortho-, meta- and para-substituted imidazolylmethylstyrenes of the formula I ##STR1## and to a process for their preparation. The compounds according to the invention are distinguished by having a specific inhibitory effect on the synthesis of thromboxane, and hence they can be used as medicaments.

Imidazolyl compounds and their use as medicaments

The present invention relates to 4-substituted .DELTA.2-imidazolinyl-thioethers and to intermediates and processes for their preparation. The components according to the invention are distinguished in particular by their platelet aggregation-inhibiting and hypotensive action.

4-substituted .DELTA.2-imidazolinyl-thioethers with prostaglandin-like

The present invention relates to 5-substituted .DELTA.2-imidazolinyl-thioethers and to intermediates and processes for their preparation. The components according to the invention are distinguished in particular by their platelet aggregation-inhibiting and hypotensive action.

5-substituted .DELTA.2-imidazolinyl-thioethers with prostaglandin-like

The present invention relates to .DELTA..sup.1 -pyrroline thiolactim ethers of the general formula I ##STR1## which have a more specific action and/or a longer-lasting action than PGI.sub.2, and to a process for their preparation. The compounds are distinguished by a platelet aggregation-inhibiting action and a blood vessel-relaxing and hypotensive action, and can therefore be used as medicaments.

.DELTA..sup.1 -Pyrroline thiolactim ethers and a process for their

What is disclosed are prostacyclin analogs of the general formula I ##STR1## which have a more specific action and/or a longer action than the naturally occurring prostacyclin PGI.sub.2, as well as intermediate products for their preparation and a process for their preparation. The compounds of formula I are distinguished by inhibitory action on thrombocyte aggregation and by relaxation of the vascular walls, in particular of the coronary arteries. They can thus be used as medicaments.

Growing community of inventors

Bad Soden am Taunus, Germany

Wilhelm Bartmann